These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 29994840)
1. Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors? Filippatos TD; Christopoulou EC; Elisaf MS Curr Opin Lipidol; 2018 Aug; 29(4):333-339. PubMed ID: 29994840 [TBL] [Abstract][Full Text] [Related]
2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
3. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367 [TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
5. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. Filippatos TD; Kei A; Rizos CV; Elisaf MS J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253 [TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332 [TBL] [Abstract][Full Text] [Related]
14. PCSK9: from biology to clinical applications. Blanchard V; Khantalin I; Ramin-Mangata S; Chémello K; Nativel B; Lambert G Pathology; 2019 Feb; 51(2):177-183. PubMed ID: 30522786 [TBL] [Abstract][Full Text] [Related]
15. Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. Brown M; Ahmed S Toxicol Appl Pharmacol; 2019 May; 370():170-177. PubMed ID: 30914377 [TBL] [Abstract][Full Text] [Related]
16. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes. Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498 [TBL] [Abstract][Full Text] [Related]
17. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079 [TBL] [Abstract][Full Text] [Related]
18. PCSK9 targets important for lipid metabolism. Schulz R; Schlüter KD Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216 [TBL] [Abstract][Full Text] [Related]
19. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. Tziomalos K Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622 [TBL] [Abstract][Full Text] [Related]